KPTI News and Press, Karyopharm Therapeutics Inc. From 06/09/21

Photo by ExperienceInteriors/E+ via Getty Images Karyopharm Therapeutics ([[KPTI]] +3.9%) announced the updated results from a Phase I/II study for eltanexor against hypomethylating agent ((HMA)) refractory myelodysplastic syndrome ((MDS)). The presentation at the 2021 American Society o...

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress PR Newswire NEWTON, Mass. , June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharm...

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS PR Newswire --Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- ...

A commercial-stage pharmaceutical company pioneering novel cancer therapies, Karyopharm Therapeutics (KPTI) announces key management changes to its commercial organization.John Demaree, chief commercial officer, and Perry Monaco, Senior VP of Sales, will be leaving to pursue ot...

Karyopharm Announces Key Changes to Its Commercial Leadership Team − Sohanya Cheng, Formerly of Amgen and Arrowhead Pharmaceuticals, Appointed as Head of Sales and Commercial Operations - − Payman Darouian, Formerly of Novartis, Bristol Myers Squibb, and Sanofi...

Karyopharm Therapeutics ([[KPTI]] -1.2%) announces that three new strength tablets for XPOVIO, the company's oral Selective Inhibitor of Nuclear Export ((SINE)) medicine, are now commercially available.The availability of these additional strength tablets follows a U.S. FDA approval in A...

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets -- Three New Strength Tablets Approved by the FDA: 40 mg, 50 mg and 60 mg -- -- New Tablet Strengths Provide Additional Patient Convenience and Dosing Flexibility -- PR Newswire...

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma -- NEXPOVIO is the First and Only Nuclear Expo...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference PR Newswire NEWTON, Mass. , May 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today anno...